PCSK9 and familial hyperaldosteronism: In fact, Mandraffino et al. demonstrated that PCSK9-i significantly reduced PWV compared to ezetimibe in a real-word setting of FH subjects; furthermore, Cicero et al. found a significant improvement of PWV already after three months of PCSK9-i addition.